DVA DaVita

Q3 2025 10-Q

Filed: Oct 29, 2025Period ending Sep 30, 2025

Health Care

Services-Misc Health & Allied Services, NECSEC EDGAR

DaVita (DVA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 29, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Total consolidated revenue $10.02B YTD Q3 2025 vs. $9.52B YTD Q3 2024, up 5.3%; U.S. dialysis revenue $8.72B up 2.5%, ancillary services $1.36B up 25.5%
• U.S. dialysis operating income $1.53B YTD Q3 2025 vs. $1.63B YTD Q3 2024, down 5.9%; adjusted operating income $1.55B down 2.3%

+3 more insights

Risk Factors

• No new or materially changed risk factors since 2024 10-K filing
• Regulatory risk from potential changes in Medicare and Medicaid reimbursement rates, ongoing impact on revenue stability

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$3.4B

▲ +4.8% YoY▲ +1.2% QoQ

Net Income

$150M

▼ -30.0% YoY▼ -24.6% QoQ

Operating Margin

14.8%

▼ -160bp YoY▼ -113bp QoQ

Net Margin

4.4%

▼ -218bp YoY▼ -150bp QoQ

ROE

-26.3%

Total Assets

$17.6B

EPS (Diluted)

$2.05

▼ -18.3% YoY▼ -20.2% QoQ

Operating Cash Flow

$842M

▲ +3.8% YoY▲ +159.5% QoQ

Source: XBRL data from DaVita Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other DaVita Quarterly Reports

Q2 2025 10-Q

Get deeper insights on DaVita

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.